APO-MILRINONE INJECTABLE SOLUTION

Negara: Kanada

Bahasa: Inggris

Sumber: Health Canada

Beli Sekarang

Unduh Karakteristik produk (SPC)
13-07-2004

Bahan aktif:

MILRINONE (MILRINONE LACTATE)

Tersedia dari:

APOTEX INC

Kode ATC:

C01CE02

INN (Nama Internasional):

MILRINONE

Dosis:

1.0MG

Bentuk farmasi:

SOLUTION

Komposisi:

MILRINONE (MILRINONE LACTATE) 1.0MG

Rute administrasi :

INTRAVENOUS

Unit dalam paket:

10/20ML

Jenis Resep:

Prescription

Area terapi:

CARDIOTONIC AGENTS

Ringkasan produk:

Active ingredient group (AIG) number: 0131285001; AHFS:

Status otorisasi:

CANCELLED POST MARKET

Tanggal Otorisasi:

2013-08-02

Karakteristik produk

                                PRODUCT MONOGRAPH
APO-MILRINONE INJECTABLE
MILRINONE LACTATE INJECTION
10 ML AND 20 ML (1 MG MILRINONE/ML)
INOTROPE / VASODILATOR
APOTEX INC.
DATE OF PREPARATION:
150 SIGNET DRIVE
April 30, 2004
WESTON, ONTARIO
M9L 1T9
Submission Control No.: 083487
- 1 -
PRODUCT MONOGRAPH
APO-MILRINONE Injectable
Milrinone Lactate Injection
10 mL and 20 mL (1 mg milrinone/mL)
THERAPEUTIC CLASSIFICATION
Inotrope / Vasodilator
ACTIONS AND CLINICAL PHARMACOLOGY
Milrinone lactate injection is a positive inotrope and vasodilator,
with little chronotropic activity,
different in structure and mode of action from either the digitalis
glycosides or catecholamines.
Milrinone, at relevant inotropic and vasorelaxant concentrations, is a
selective inhibitor of peak
III cAMP phosphodiesterase isozyme in cardiac and vascular muscle.
This inhibitory action is
consistent with cAMP mediated increases in intracellular ionized
calcium and contractile force in
cardiac muscle, as well as with cAMP dependent contractile protein
phosphorylation and
relaxation in vascular muscle. Additional experimental evidence also
indicates that it is not a
beta-adrenergic agonist, nor does it inhibit sodium-potassium
adenosine triphosphatase activity
as do the digitalis glycosides.
Clinical studies in patients with congestive heart failure have shown
that milrinone lactate
injection produces dose and plasma level-related increase in left
ventricular dP/dt, increase in
forearm blood flow indicating a direct arterial vasodilator activity
of the drug, and improves
diastolic function as evidenced by improvement in left ventricular
diastolic relaxation.
Studies in normal subjects have shown that milrinone lactate injection
produces increases in the
slope of the left ventricular pressure-dimension relationship,
indicating a direct inotropic effect of
the drug. Both the inotropic and vasodilatory effects have been
observed over the therapeutic
range of milrinone plasma concentrations of 100 to 300 ng/mL.
- 2 -
PHARMACOKINETICS
Following intravenous loading injections of 12
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Karakteristik produk Karakteristik produk Prancis 10-04-2013

Peringatan pencarian terkait dengan produk ini